News Breaks |
|
|
| January 30, 2013 |
| 15:31 EDT |  | STJ, BLK | BlackRock reports 6.37% passive stake in St. Jude Medical
|
|
|
News For STJ;BLK From The Last 14 Days Check below for free stories on STJ;BLK the last two weeks. |
|
|
| June 17, 2013 |
| 12:57 EDT |  | BLK | BlackRock to host investor day
 Subscribe for More Information |
|
| June 14, 2013 |
| 15:36 EDT |  | BLK | BlackRock volatility elevated into investor day
Subscribe for More Information |
|
| 11:16 EDT |  | BLK | BlackRock stock-fund leader taking medical leave, WSJ reports
Subscribe for More Information |
|
| 05:56 EDT | | BLK | BlackRock's stock funds fall behind many U.S. competitors, WSJ reports
Subscribe for More Information |
|
| June 12, 2013 |
| 14:21 EDT | | BLK | BlackRock volatility increases on wide price movement
BlackRock June and July call option implied volatility is at 28, October is at 27; compared to its 26-week average of 23 according to Track Data, suggesting larger price movement into a company hosted investor day on June 18. |
|
| June 11, 2013 |
| 16:08 EDT | | STJ | FDA approves St. Jude Medical devices with new safety features
St. Jude Medical announced FDA approval of its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators. The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery. |
|
| June 10, 2013 |
| 12:22 EDT | | STJ | St. Jude's Durata backed by doctor who found Riata defect, Bloomberg says
Subscribe for More Information |
|
| June 7, 2013 |
| 11:05 EDT | | STJ | St. Jude invests $40M in Spinal Modulation, gets exclusive option to acquire
St. Jude Medical and privately-held Spinal Modulation announced that they have entered into a series of agreements under which St. Jude Medical made a $40M equity investment in Spinal Modulation, a company that has developed an innovative neuromodulation therapy that provides a new pain management option for patients with chronic, intractable pain. The agreement provides St. Jude Medical with an exclusive option to distribute the Axium Neurostimulator System, developed and manufactured by Spinal Modulation, in international markets where it is approved for sale. Additionally, St. Jude Medical will have the exclusive option to acquire the company for up to $300M plus certain revenue-based milestones following U.S. commercialization. |
|
| 08:17 EDT | | BLK | PIMCO supports BofA's $8.5B mortgage settledment, Bloomberg reports
Bank of America's (BAC) $8.5B mortgage-bond settlement is “outstanding” for investors, says Kent Smith, an executive VP at Pimco who helped negotiate the agreement, and who testified in a trial over the agreement, reports Bloomberg. The settlement was reached after an investor group that included Pimco and BlackRock (BLK) at first demanded $12B. The accord resolves claims from Countrywide Financial mortgage-bond investors over loans bundled into securities. AIG (AIG) is fighting the settlement, saying Bank of America isn’t paying enough to compensate investors. Reference Link |
|
| June 6, 2013 |
| 07:17 EDT | | BLK | Pershing to host a conference
Subscribe for More Information |
| |
| June 4, 2013 |
| 13:22 EDT | | BLK | BlackRock close to purchase of Gafisa unit, Dow Jones reports
Subscribe for More Information |
|
| 11:58 EDT |  | STJ | Failure of St. Jude Medical Durata could be cause for concern, says Wells Fargo
Wells Fargo believes that the failure of a single Durata lead made by St. Jude could justify concerns about potential Durata failures. The firm notes, however, that the device short circuited, and that the company plans to unveil new leads that switch vectors in order to counter short circuits. The firm keeps a Market Perform rating on St. Jude. |
|
| 08:06 EDT | | STJ | St. Jude Medical initiates EnligHTN IV Renal Denervation Study
St. Jude Medical announced U.S. Food and Drug Administration approval to begin the EnligHTN IV Renal Denervation Study, the first U.S. trial using the EnligHTN Multi-Electrode Renal Denervation System to treat patients with drug-resistant high blood pressure. The EnligHTN IV study is a randomized, single-blind, controlled, multi-center trial to demonstrate the safety and effectiveness of the EnligHTN Renal Denervation System in reducing systolic blood pressure when measured in an office setting. The study will enroll approximately 590 patients between the ages of 18 and 80 with an office systolic blood pressure of 160 mmHg or greater, who are taking three or more antihypertensive medications including a diuretic. Study patients will be enrolled at up to 80 sites in the U.S. and Canada. |
|
| 07:54 EDT | | BLK | Morningstar Research to host a conference
10th Annual Investment Conference is being held in Toronto on June 4-5. |
|
| 07:53 EDT | | BLK | Deutsche Bank to host a conference
Subscribe for More Information |
|
|
|
|
|
